{"id":"alprazolam-aerobic-exercise","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Sedation / drowsiness"},{"rate":"15-30","effect":"Dizziness"},{"rate":null,"effect":"Dependence / withdrawal risk"},{"rate":"10-20","effect":"Cognitive impairment"},{"rate":null,"effect":"Muscle fatigue (exercise-related)"}]},"_chembl":{"chemblId":"CHEMBL661","moleculeType":"Small molecule","molecularWeight":"308.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alprazolam is a benzodiazepine that potentiates GABA-A receptor signaling, increasing inhibitory neurotransmission and reducing neuronal excitability. Aerobic exercise complements this by promoting neuroplasticity, increasing brain-derived neurotrophic factor (BDNF), improving sleep quality, and enhancing cardiovascular efficiency—all of which contribute to anxiolytic and mood-stabilizing effects. The combination leverages both pharmacological and behavioral mechanisms to address anxiety disorders.","oneSentence":"Alprazolam reduces anxiety and panic by enhancing GABAergic inhibition in the central nervous system, while aerobic exercise improves mood and anxiety symptoms through neurobiological adaptations including increased endorphin release and improved cardiovascular function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:02.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders with panic attacks"},{"name":"Generalized anxiety disorder (GAD)"}]},"trialDetails":[{"nctId":"NCT00803400","phase":"PHASE4","title":"Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment","status":"COMPLETED","sponsor":"University of Buenos Aires","startDate":"2008-10-01","conditions":"Panic Disorder","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Exercise group"],"phase":"marketed","status":"active","brandName":"Alprazolam + Aerobic exercise","genericName":"Alprazolam + Aerobic exercise","companyName":"University of Buenos Aires","companyId":"university-of-buenos-aires","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alprazolam reduces anxiety and panic by enhancing GABAergic inhibition in the central nervous system, while aerobic exercise improves mood and anxiety symptoms through neurobiological adaptations including increased endorphin release and improved cardiovascular function. Used for Anxiety disorders with panic attacks, Generalized anxiety disorder (GAD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}